<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00941681</url>
  </required_header>
  <id_info>
    <org_study_id>CY 1021</org_study_id>
    <nct_id>NCT00941681</nct_id>
  </id_info>
  <brief_title>Pharmacokinetics of Oral CK-1827452 in Patients With Stable Heart Failure</brief_title>
  <official_title>An Open Label Study to Investigate the Pharmacokinetics of CK-1827452 Administered Orally to Patients With Stable Heart Failure</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Cytokinetics</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Cytokinetics</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is designed to understand the pharmacokinetics of different oral formulations of
      CK-1827452 being considered for future studies in patients with heart failure. This study
      will compare the pharmacokinetics and safety and tolerability of both modified-release (MR)
      and immediate-release (IR) oral formulations of CK-1827452.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>April 2009</start_date>
  <completion_date type="Actual">October 2009</completion_date>
  <primary_completion_date type="Actual">October 2009</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>C Max (Day 1, Dose 1)</measure>
    <time_frame>1 day</time_frame>
    <description>Maximum plasma concentration (C max) measured in nanograms per milliliter (ng/mL) post first dose and pre second dose on day 1. Doses are approximately 12 hours apart in cohort 1 and 3 and 8 hours apart in cohort 2.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>T Max (Day 1, Dose 1)</measure>
    <time_frame>1 day</time_frame>
    <description>Time of observed maximum plasma concentration (T max) measured in hours (hr) post first dose and pre second dose on day 1. Doses are approximately 12 hours apart in cohort 1 and 3 and 8 hours apart in cohort 2.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>AUC (Day 1, Dose 1)</measure>
    <time_frame>1 day</time_frame>
    <description>Area under the curve (AUC) measured in hours * nanograms per milliliter (hr*ng/mL) post first dose and pre second dose on day 1. Doses are approximately 12 hours apart in cohort 1 and 3 and 8 hours apart in cohort 2.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>C Max (Day 10)</measure>
    <time_frame>1 day</time_frame>
    <description>Maximum plasma concentration (C max) measured in nanograms per milliliter (ng/mL) post dose on day 10. Only one dose was administered on day 10 (final dose of study).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>T Max (Day 10)</measure>
    <time_frame>1 day</time_frame>
    <description>Time of observed maximum plasma concentration (T max) measured in hours (hr) post dose on day 10. Only one dose was administered on day 10 (final dose of study).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>AUC (Day 10)</measure>
    <time_frame>1 day</time_frame>
    <description>Area under the curve (AUC) measured in hours * nanograms per milliliter (hr*ng/mL) post dose on day 10. Only one dose was administered on day 10 (final dose of study).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Evaluate the Safety and Tolerability of Oral Formulations of CK-1827452 When Dosed to Steady-state in Patients With Stable Heart Failure.</measure>
    <time_frame>1 week</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">35</enrollment>
  <condition>Heart Failure</condition>
  <arm_group>
    <arm_group_label>Cohort 1: MR 50 mg BID</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Modified-release (MR) 50 mg dose of CK-1827452 twice a day (BID) for 10 days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 2: IR 37.5 mg TID</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Immediate-release (IR) 37.5 mg dose of CK-1827452 three times a day (TID) for 10 days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 3: MR 100 mg BID</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Modified-release (MR) 100 mg dose of CK-1827452 twice a day (BID) for 10 days</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CK-1827452</intervention_name>
    <description>50 mg MR CK-1827452 BID for 10 days</description>
    <arm_group_label>Cohort 1: MR 50 mg BID</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CK-1827452</intervention_name>
    <description>37.5 mg IR CK-1827452 TID for 10 days</description>
    <arm_group_label>Cohort 2: IR 37.5 mg TID</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CK-1827452</intervention_name>
    <description>100 mg MR CK-1827452 BID for 10 days</description>
    <arm_group_label>Cohort 3: MR 100 mg BID</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. The patient has signed an Informed Consent Form/Patient Information Sheet for this
             study approved by the governing Institutional Review Board (IRB) or Independent Ethics
             Committee (IEC)

          2. The patient is at least 18 years old at the time of consent

          3. Left ventricular ejection fraction (LVEF) ≤ 35% as determined by the Investigator
             within 3 weeks prior to enrollment

          4. Treated for at least 4 weeks with a beta blocker and an ACE inhibitor (and/or an ARB)
             unless not tolerated. If prescribed, diuretics must have been administered according
             to a consistent regimen for at least 4 weeks.

          5. Diagnosed with heart failure for ≥ 3 months prior to enrollment

          6. Patient is considered to be an appropriate candidate for study enrollment as
             determined by the patient's clinical laboratory findings, vital signs and ECGs within
             normal range, or if outside of the normal range not deemed clinically significant in
             the opinion of the Investigator

          7. For female patients only: The patient is post-menopausal (≥ 1 year) or sterilized, or
             if she is of childbearing potential, she is not breastfeeding, her pregnancy test is
             negative, she has no intention to become pregnant during the course of the study, and
             she is using contraceptive drugs or devices. For male patients only: Male patients
             agree for the duration of the study and 10 weeks after the end of the study to use a
             condom during sexual intercourse with female partners who are of reproductive
             potential and to have female partners use an additional effective means of
             contraception (eg, diaphragm plus spermicide, or oral contraceptives) or the male
             subject must agree to abstain from sexual intercourse for 10 weeks after the end of
             the study.

        Exclusion Criteria:

          1. Patient has been hospitalised for heart failure, acute coronary syndrome, myocardial
             infarction, coronary revascularisation, transient ischemic attack or stroke, cardiac
             arrhythmia, or major surgery within 6 weeks prior to enrollment

          2. Poorly controlled hypertension defined as blood pressure &gt; 150/95 mmHg, documented on
             at least 2 separate occasions prior to enrollment

          3. The patient has a supine heart rate ≥ 100 beats per minute after 10 minutes of rest

          4. Patient has a troponin I at screening that is above the upper limit of normal

          5. The patient has severe aortic or mitral stenosis

          6. The patient has active myocarditis; clinically significant restrictive, constrictive,
             or hypertrophic obstructive cardiomyopathy; clinically significant congenital heart
             disease; history of major organ transplantation

          7. The patient has Canadian Cardiovascular Society Class IV angina

          8. Patient is on chronic anti-arrhythmic therapy, with the exception of amiodarone

          9. Patient has impaired renal function defined as an estimated GFR ≤ 30 ml/min/1.73 m2
             calculated by the Modification of Diet in Renal Disease (MDRD) equation

         10. Patient is currently taking, or has taken within 14 days prior to enrollment, a potent
             CYP3A4 inhibitor (medication or food). Patient is currently taking, or has taken
             within 28 days prior to enrollment, a potent CYP3A4 inducer (medication or food).

         11. The patient has hepatic impairment defined as a total bilirubin &gt; 3 mg/dL, or an ALT
             or AST &gt; 2 times the upper limit of normal

         12. Concomitant non-cardiovascular disease that is expected to reduce life expectancy to
             less than 1 year

         13. The patient has received an investigational drug or device within 30 days or 5
             half-lives, whichever is greater, of enrollment

         14. Patient has, in the opinion of the Investigator, a condition that compromises the
             ability of the subject to give written informed consent or to comply with study
             procedures, including scheduled self-administration of oral CK-1827452

         15. The patient has had any prior treatment with CK-1827452
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Cardio-Reanimation Centre</name>
      <address>
        <city>Tbilisi</city>
        <country>Georgia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Diagnostic Services Clinic</name>
      <address>
        <city>Tbilisi</city>
        <country>Georgia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tbilisi State Medical University Clinic #1</name>
      <address>
        <city>Tbilisi</city>
        <country>Georgia</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Georgia</country>
  </location_countries>
  <verification_date>February 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 15, 2009</study_first_submitted>
  <study_first_submitted_qc>July 16, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 17, 2009</study_first_posted>
  <results_first_submitted>October 29, 2010</results_first_submitted>
  <results_first_submitted_qc>November 22, 2010</results_first_submitted_qc>
  <results_first_posted type="Estimate">December 21, 2010</results_first_posted>
  <last_update_submitted>February 6, 2013</last_update_submitted>
  <last_update_submitted_qc>February 6, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 12, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>omecamtiv mecarbil</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Failure</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Cohort 1: MR 50 mg BID</title>
          <description>Modified-release (MR) 50 mg dose of CK-1827452 twice a day (BID) for 10 days.</description>
        </group>
        <group group_id="P2">
          <title>Cohort 2: IR 37.5 mg TID</title>
          <description>Immediate-release (IR) 37.5 mg dose of CK-1827452 three times a day (TID) for 10 days.</description>
        </group>
        <group group_id="P3">
          <title>Cohort 3: MR 100 mg BID</title>
          <description>Modified-release (MR) 100 mg dose of CK-1827452 twice a day (BID) for 10 days</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
                <participants group_id="P2" count="11"/>
                <participants group_id="P3" count="12"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
                <participants group_id="P2" count="10"/>
                <participants group_id="P3" count="12"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Cohort 1: MR 50 mg BID</title>
          <description>Modified-release (MR) 50 mg dose of CK-1827452 twice a day (BID) for 10 days.</description>
        </group>
        <group group_id="B2">
          <title>Cohort 2: IR 37.5 mg TID</title>
          <description>Immediate-release (IR) 37.5 mg dose of CK-1827452 three times a day (TID) for 10 days.</description>
        </group>
        <group group_id="B3">
          <title>Cohort 3: MR 100 mg BID</title>
          <description>Modified-release (MR) 100 mg dose of CK-1827452 twice a day (BID) for 10 days</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="12"/>
            <count group_id="B2" value="11"/>
            <count group_id="B3" value="12"/>
            <count group_id="B4" value="35"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="6"/>
                    <measurement group_id="B4" value="21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="6"/>
                    <measurement group_id="B4" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="64.1" spread="7.74"/>
                    <measurement group_id="B2" value="61.1" spread="7.97"/>
                    <measurement group_id="B3" value="62.4" spread="11.51"/>
                    <measurement group_id="B4" value="62.6" spread="9.08"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="4"/>
                    <measurement group_id="B4" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="8"/>
                    <measurement group_id="B4" value="24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Georgia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                    <measurement group_id="B2" value="11"/>
                    <measurement group_id="B3" value="12"/>
                    <measurement group_id="B4" value="35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>C Max (Day 1, Dose 1)</title>
        <description>Maximum plasma concentration (C max) measured in nanograms per milliliter (ng/mL) post first dose and pre second dose on day 1. Doses are approximately 12 hours apart in cohort 1 and 3 and 8 hours apart in cohort 2.</description>
        <time_frame>1 day</time_frame>
        <population>PK population (4 patients excluded from cohort 3 analysis due to improper dosing).</population>
        <group_list>
          <group group_id="O1">
            <title>Cohort 1: MR 50 mg BID</title>
            <description>Modified-release (MR) 50 mg dose of CK-1827452 twice a day (BID) for 10 days.</description>
          </group>
          <group group_id="O2">
            <title>Cohort 2: IR 37.5 mg TID</title>
            <description>Immediate-release (IR) 37.5 mg dose of CK-1827452 three times a day (TID) for 10 days.</description>
          </group>
          <group group_id="O3">
            <title>Cohort 3: MR 100 mg BID</title>
            <description>Modified-release (MR) 100 mg dose of CK-1827452 twice a day (BID) for 10 days</description>
          </group>
        </group_list>
        <measure>
          <title>C Max (Day 1, Dose 1)</title>
          <description>Maximum plasma concentration (C max) measured in nanograms per milliliter (ng/mL) post first dose and pre second dose on day 1. Doses are approximately 12 hours apart in cohort 1 and 3 and 8 hours apart in cohort 2.</description>
          <population>PK population (4 patients excluded from cohort 3 analysis due to improper dosing).</population>
          <units>ng/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="11"/>
                <count group_id="O3" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="58" spread="27"/>
                    <measurement group_id="O2" value="243" spread="148"/>
                    <measurement group_id="O3" value="209" spread="164"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Evaluate the Safety and Tolerability of Oral Formulations of CK-1827452 When Dosed to Steady-state in Patients With Stable Heart Failure.</title>
        <time_frame>1 week</time_frame>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>T Max (Day 1, Dose 1)</title>
        <description>Time of observed maximum plasma concentration (T max) measured in hours (hr) post first dose and pre second dose on day 1. Doses are approximately 12 hours apart in cohort 1 and 3 and 8 hours apart in cohort 2.</description>
        <time_frame>1 day</time_frame>
        <population>PK population (4 patients excluded from cohort 3 analysis due to improper dosing).</population>
        <group_list>
          <group group_id="O1">
            <title>Cohort 1: MR 50 mg BID</title>
            <description>Modified-release (MR) 50 mg dose of CK-1827452 twice a day (BID) for 10 days.</description>
          </group>
          <group group_id="O2">
            <title>Cohort 2: IR 37.5 mg TID</title>
            <description>Immediate-release (IR) 37.5 mg dose of CK-1827452 three times a day (TID) for 10 days.</description>
          </group>
          <group group_id="O3">
            <title>Cohort 3: MR 100 mg BID</title>
            <description>Modified-release (MR) 100 mg dose of CK-1827452 twice a day (BID) for 10 days</description>
          </group>
        </group_list>
        <measure>
          <title>T Max (Day 1, Dose 1)</title>
          <description>Time of observed maximum plasma concentration (T max) measured in hours (hr) post first dose and pre second dose on day 1. Doses are approximately 12 hours apart in cohort 1 and 3 and 8 hours apart in cohort 2.</description>
          <population>PK population (4 patients excluded from cohort 3 analysis due to improper dosing).</population>
          <units>hr</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="11"/>
                <count group_id="O3" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.5" spread="2.9"/>
                    <measurement group_id="O2" value="3.7" spread="3.7"/>
                    <measurement group_id="O3" value="3.5" spread="3.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>AUC (Day 1, Dose 1)</title>
        <description>Area under the curve (AUC) measured in hours * nanograms per milliliter (hr*ng/mL) post first dose and pre second dose on day 1. Doses are approximately 12 hours apart in cohort 1 and 3 and 8 hours apart in cohort 2.</description>
        <time_frame>1 day</time_frame>
        <population>PK population (4 patients excluded from cohort 3 analysis due to improper dosing).</population>
        <group_list>
          <group group_id="O1">
            <title>Cohort 1: MR 50 mg BID</title>
            <description>Modified-release (MR) 50 mg dose of CK-1827452 twice a day (BID) for 10 days.</description>
          </group>
          <group group_id="O2">
            <title>Cohort 2: IR 37.5 mg TID</title>
            <description>Immediate-release (IR) 37.5 mg dose of CK-1827452 three times a day (TID) for 10 days.</description>
          </group>
          <group group_id="O3">
            <title>Cohort 3: MR 100 mg BID</title>
            <description>Modified-release (MR) 100 mg dose of CK-1827452 twice a day (BID) for 10 days</description>
          </group>
        </group_list>
        <measure>
          <title>AUC (Day 1, Dose 1)</title>
          <description>Area under the curve (AUC) measured in hours * nanograms per milliliter (hr*ng/mL) post first dose and pre second dose on day 1. Doses are approximately 12 hours apart in cohort 1 and 3 and 8 hours apart in cohort 2.</description>
          <population>PK population (4 patients excluded from cohort 3 analysis due to improper dosing).</population>
          <units>hr*ng/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="11"/>
                <count group_id="O3" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="446" spread="206"/>
                    <measurement group_id="O2" value="1003" spread="387"/>
                    <measurement group_id="O3" value="1650" spread="1354"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>C Max (Day 10)</title>
        <description>Maximum plasma concentration (C max) measured in nanograms per milliliter (ng/mL) post dose on day 10. Only one dose was administered on day 10 (final dose of study).</description>
        <time_frame>1 day</time_frame>
        <population>PK population (4 patients excluded from cohort 3 analysis due to improper dosing and 1 patient excluded from cohort 2 due to sudden death).</population>
        <group_list>
          <group group_id="O1">
            <title>Cohort 1: MR 50 mg BID</title>
            <description>Modified-release (MR) 50 mg dose of CK-1827452 twice a day (BID) for 10 days.</description>
          </group>
          <group group_id="O2">
            <title>Cohort 2: IR 37.5 mg TID</title>
            <description>Immediate-release (IR) 37.5 mg dose of CK-1827452 three times a day (TID) for 10 days.</description>
          </group>
          <group group_id="O3">
            <title>Cohort 3: MR 100 mg BID</title>
            <description>Modified-release (MR) 100 mg dose of CK-1827452 twice a day (BID) for 10 days</description>
          </group>
        </group_list>
        <measure>
          <title>C Max (Day 10)</title>
          <description>Maximum plasma concentration (C max) measured in nanograms per milliliter (ng/mL) post dose on day 10. Only one dose was administered on day 10 (final dose of study).</description>
          <population>PK population (4 patients excluded from cohort 3 analysis due to improper dosing and 1 patient excluded from cohort 2 due to sudden death).</population>
          <units>ng/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="10"/>
                <count group_id="O3" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="205" spread="111"/>
                    <measurement group_id="O2" value="420" spread="158"/>
                    <measurement group_id="O3" value="704" spread="494"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>T Max (Day 10)</title>
        <description>Time of observed maximum plasma concentration (T max) measured in hours (hr) post dose on day 10. Only one dose was administered on day 10 (final dose of study).</description>
        <time_frame>1 day</time_frame>
        <population>PK population (4 patients excluded from cohort 3 analysis due to improper dosing and 1 patient excluded from cohort 2 due to sudden death).</population>
        <group_list>
          <group group_id="O1">
            <title>Cohort 1: MR 50 mg BID</title>
            <description>Modified-release (MR) 50 mg dose of CK-1827452 twice a day (BID) for 10 days.</description>
          </group>
          <group group_id="O2">
            <title>Cohort 2: IR 37.5 mg TID</title>
            <description>Immediate-release (IR) 37.5 mg dose of CK-1827452 three times a day (TID) for 10 days.</description>
          </group>
          <group group_id="O3">
            <title>Cohort 3: MR 100 mg BID</title>
            <description>Modified-release (MR) 100 mg dose of CK-1827452 twice a day (BID) for 10 days</description>
          </group>
        </group_list>
        <measure>
          <title>T Max (Day 10)</title>
          <description>Time of observed maximum plasma concentration (T max) measured in hours (hr) post dose on day 10. Only one dose was administered on day 10 (final dose of study).</description>
          <population>PK population (4 patients excluded from cohort 3 analysis due to improper dosing and 1 patient excluded from cohort 2 due to sudden death).</population>
          <units>hr</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="10"/>
                <count group_id="O3" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.8" spread="0.9"/>
                    <measurement group_id="O2" value="1.8" spread="1.1"/>
                    <measurement group_id="O3" value="2.7" spread="1.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>AUC (Day 10)</title>
        <description>Area under the curve (AUC) measured in hours * nanograms per milliliter (hr*ng/mL) post dose on day 10. Only one dose was administered on day 10 (final dose of study).</description>
        <time_frame>1 day</time_frame>
        <population>PK population (4 patients excluded from cohort 3 analysis due to improper dosing and 1 patient excluded from cohort 2 due to sudden death).</population>
        <group_list>
          <group group_id="O1">
            <title>Cohort 1: MR 50 mg BID</title>
            <description>Modified-release (MR) 50 mg dose of CK-1827452 twice a day (BID) for 10 days.</description>
          </group>
          <group group_id="O2">
            <title>Cohort 2: IR 37.5 mg TID</title>
            <description>Immediate-release (IR) 37.5 mg dose of CK-1827452 three times a day (TID) for 10 days.</description>
          </group>
          <group group_id="O3">
            <title>Cohort 3: MR 100 mg BID</title>
            <description>Modified-release (MR) 100 mg dose of CK-1827452 twice a day (BID) for 10 days</description>
          </group>
        </group_list>
        <measure>
          <title>AUC (Day 10)</title>
          <description>Area under the curve (AUC) measured in hours * nanograms per milliliter (hr*ng/mL) post dose on day 10. Only one dose was administered on day 10 (final dose of study).</description>
          <population>PK population (4 patients excluded from cohort 3 analysis due to improper dosing and 1 patient excluded from cohort 2 due to sudden death).</population>
          <units>hr*ng/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="10"/>
                <count group_id="O3" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1886" spread="1002"/>
                    <measurement group_id="O2" value="2118" spread="623"/>
                    <measurement group_id="O3" value="6457" spread="5147"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Cohort 1: MR 50 mg BID</title>
          <description>Modified-release (MR) 50 mg dose of CK-1827452 twice a day (BID) for 10 days.</description>
        </group>
        <group group_id="E2">
          <title>Cohort 2: IR 37.5 mg TID</title>
          <description>Immediate-release (IR) 37.5 mg dose of CK-1827452 three times a day (TID) for 10 days.</description>
        </group>
        <group group_id="E3">
          <title>Cohort 3: MR 100 mg BID</title>
          <description>Modified-release (MR) 100 mg dose of CK-1827452 twice a day (BID) for 10 days</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedRA 10.0</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Sudden death</sub_title>
                <description>Reported as unrelated to treatment by Investigator.</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>MedRA 10.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Ventricular extrasystoles</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Influenza like illness</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Sponsor intends to publish the results of the trial in collaboration with the Investigators.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Project Manager</name_or_title>
      <organization>Cytokinetics, Inc.</organization>
      <phone>650-624-2918</phone>
    </point_of_contact>
  </clinical_results>
</clinical_study>

